MX2007009091A - Formulaciones de polipeptido liquidas estabilizadas. - Google Patents
Formulaciones de polipeptido liquidas estabilizadas.Info
- Publication number
- MX2007009091A MX2007009091A MX2007009091A MX2007009091A MX2007009091A MX 2007009091 A MX2007009091 A MX 2007009091A MX 2007009091 A MX2007009091 A MX 2007009091A MX 2007009091 A MX2007009091 A MX 2007009091A MX 2007009091 A MX2007009091 A MX 2007009091A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- antibody
- antigen
- polypeptide
- binding polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64863905P | 2005-01-28 | 2005-01-28 | |
| PCT/US2006/004741 WO2006081587A2 (en) | 2005-01-28 | 2006-01-27 | Stabilized liquid polypeptide formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007009091A true MX2007009091A (es) | 2008-01-11 |
Family
ID=36694255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007009091A MX2007009091A (es) | 2005-01-28 | 2006-01-27 | Formulaciones de polipeptido liquidas estabilizadas. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060210557A1 (enExample) |
| EP (1) | EP1841456A2 (enExample) |
| JP (1) | JP2008528638A (enExample) |
| KR (1) | KR20070107079A (enExample) |
| CN (1) | CN101111264A (enExample) |
| AR (1) | AR052469A1 (enExample) |
| AU (1) | AU2006207901A1 (enExample) |
| BR (1) | BRPI0606867A2 (enExample) |
| CA (1) | CA2595380A1 (enExample) |
| CR (1) | CR9294A (enExample) |
| DO (1) | DOP2006000022A (enExample) |
| GT (1) | GT200600033A (enExample) |
| IL (1) | IL184341A0 (enExample) |
| MX (1) | MX2007009091A (enExample) |
| NO (1) | NO20073666L (enExample) |
| PA (1) | PA8661401A1 (enExample) |
| PE (1) | PE20061201A1 (enExample) |
| RU (1) | RU2007124933A (enExample) |
| SV (1) | SV2008002394A (enExample) |
| TW (1) | TW200638943A (enExample) |
| UY (1) | UY29350A1 (enExample) |
| WO (1) | WO2006081587A2 (enExample) |
| ZA (1) | ZA200706256B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| MXPA05008156A (es) * | 2003-02-01 | 2005-09-30 | Neuralab Ltd | Inmunizacion activa para generar anticuerpos para beta-a soluble. |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| CA2582194A1 (en) * | 2004-10-05 | 2006-04-20 | Neuralab Limited | Methods and compositions for improving recombinant protein production |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| BRPI0611600B8 (pt) | 2005-06-17 | 2021-05-25 | Wyeth Corp | método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| AU2008204335B2 (en) | 2007-01-11 | 2013-06-13 | Michael Bacher | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
| NZ598881A (en) * | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| KR20210049186A (ko) * | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| NZ587632A (en) | 2008-03-14 | 2012-06-29 | Biocon Ltd | An anti-cd6 monoclonal antibody and a method thereof |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010100135A1 (en) * | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| EP2453874A2 (en) * | 2009-07-14 | 2012-05-23 | Biogen Idec MA Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US20130028933A1 (en) * | 2009-12-28 | 2013-01-31 | Ligocyte Pharmaceuticals, Inc. | Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
| CN102686241A (zh) * | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| RS59830B1 (sr) | 2010-03-01 | 2020-02-28 | Bayer Healthcare Llc | Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi) |
| JP5960120B2 (ja) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | ウイルス粒子の安定化 |
| JP5869553B2 (ja) | 2010-03-31 | 2016-02-24 | スタビリテック リミテッド | ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤 |
| GB2499480A (en) | 2010-03-31 | 2013-08-21 | Stabilitech Ltd | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| PT3170508T (pt) | 2010-06-04 | 2020-01-16 | Wyeth Llc | Formulações de vacinas |
| CN103458926B (zh) | 2010-11-11 | 2016-10-26 | 艾伯维生物技术有限公司 | 改进的高浓度抗TNF α 抗体液体制剂 |
| EP2471554A1 (en) * | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| EP2500035A1 (en) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
| MX341076B (es) | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| JP2015526409A (ja) * | 2012-07-03 | 2015-09-10 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｃ−末端及び中心エピトープａ−ベータ抗体 |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| KR102405247B1 (ko) | 2013-07-23 | 2022-06-07 | 바이오콘 리미티드 | Cd6 결합 파트너의 용도 및 이에 기초한 방법 |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| GB201320660D0 (en) * | 2013-11-22 | 2014-01-08 | Qualasept Ltd | Method |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| CR20210429A (es) | 2015-06-24 | 2021-09-24 | Hoffmann La Roche | ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562) |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
| GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN107446044B (zh) * | 2016-05-30 | 2021-04-30 | 越海百奥药业(绍兴)有限公司 | 一种纯化抗体的方法及所用缓冲液 |
| CN109843266B (zh) * | 2016-08-02 | 2023-08-11 | 安巴知识产权有限公司 | 稳定的布洛芬注射组合物 |
| PL3529274T3 (pl) | 2016-10-21 | 2024-09-09 | Biocon Limited | Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| GB201703063D0 (en) | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| AU2018321335B2 (en) * | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| MX2020005981A (es) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| EP3802590A2 (en) * | 2018-06-08 | 2021-04-14 | Argenx BVBA | Compositions and methods for treating immune thrombocytopenia |
| CN113056482A (zh) | 2018-10-18 | 2021-06-29 | 默沙东公司 | 抗rsv抗体的制剂及其使用方法 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| GB201906917D0 (en) * | 2019-05-16 | 2019-07-03 | Intract Pharma Ltd | Novel compositions |
| KR20220148804A (ko) | 2020-01-08 | 2022-11-07 | 아르젠엑스 비브이 | 천포창 장애의 치료 방법 |
| CN112451652A (zh) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
| CA3258004A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/HSA BONDING MOLECULES AND METHODS OF USE |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US6270757B1 (en) * | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
| US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| JP2000510813A (ja) * | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| ES2392073T3 (es) * | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| US20030171556A1 (en) * | 2001-12-13 | 2003-09-11 | Chi-Bom Chae | Beta-amyloid binding factors and inhibitors thereof |
| MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| AU2004229335C1 (en) * | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| PE20050627A1 (es) * | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
-
2006
- 2006-01-27 KR KR1020077019697A patent/KR20070107079A/ko not_active Withdrawn
- 2006-01-27 WO PCT/US2006/004741 patent/WO2006081587A2/en not_active Ceased
- 2006-01-27 CA CA002595380A patent/CA2595380A1/en not_active Abandoned
- 2006-01-27 PE PE2006000113A patent/PE20061201A1/es not_active Application Discontinuation
- 2006-01-27 DO DO2006000022A patent/DOP2006000022A/es unknown
- 2006-01-27 US US11/342,252 patent/US20060210557A1/en not_active Abandoned
- 2006-01-27 TW TW095103327A patent/TW200638943A/zh unknown
- 2006-01-27 RU RU2007124933/13A patent/RU2007124933A/ru not_active Application Discontinuation
- 2006-01-27 MX MX2007009091A patent/MX2007009091A/es not_active Application Discontinuation
- 2006-01-27 JP JP2007553395A patent/JP2008528638A/ja not_active Withdrawn
- 2006-01-27 PA PA20068661401A patent/PA8661401A1/es unknown
- 2006-01-27 BR BRPI0606867-7A patent/BRPI0606867A2/pt not_active IP Right Cessation
- 2006-01-27 CN CNA200680003387XA patent/CN101111264A/zh active Pending
- 2006-01-27 SV SV2006002394A patent/SV2008002394A/es not_active Application Discontinuation
- 2006-01-27 AU AU2006207901A patent/AU2006207901A1/en not_active Abandoned
- 2006-01-27 EP EP06734749A patent/EP1841456A2/en not_active Withdrawn
- 2006-01-27 GT GT200600033A patent/GT200600033A/es unknown
- 2006-01-27 AR ARP060100314A patent/AR052469A1/es not_active Application Discontinuation
- 2006-01-27 UY UY29350A patent/UY29350A1/es not_active Application Discontinuation
-
2007
- 2007-07-02 IL IL184341A patent/IL184341A0/en unknown
- 2007-07-17 NO NO20073666A patent/NO20073666L/no not_active Application Discontinuation
- 2007-07-27 ZA ZA2007/06256A patent/ZA200706256B/en unknown
- 2007-08-07 CR CR9294A patent/CR9294A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0606867A2 (pt) | 2009-07-21 |
| UY29350A1 (es) | 2006-08-31 |
| PE20061201A1 (es) | 2006-11-03 |
| KR20070107079A (ko) | 2007-11-06 |
| US20060210557A1 (en) | 2006-09-21 |
| AR052469A1 (es) | 2007-03-21 |
| TW200638943A (en) | 2006-11-16 |
| SV2008002394A (es) | 2008-02-08 |
| CN101111264A (zh) | 2008-01-23 |
| GT200600033A (es) | 2006-10-25 |
| NO20073666L (no) | 2007-10-25 |
| ZA200706256B (en) | 2009-12-30 |
| PA8661401A1 (es) | 2006-09-08 |
| JP2008528638A (ja) | 2008-07-31 |
| AU2006207901A1 (en) | 2006-08-03 |
| WO2006081587A2 (en) | 2006-08-03 |
| DOP2006000022A (es) | 2006-08-15 |
| CR9294A (es) | 2008-01-21 |
| RU2007124933A (ru) | 2009-03-10 |
| CA2595380A1 (en) | 2006-08-03 |
| WO2006081587A3 (en) | 2006-10-12 |
| IL184341A0 (en) | 2007-10-31 |
| EP1841456A2 (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2593122C (en) | Anti a beta antibody formulation | |
| US20060210557A1 (en) | Stabilized liquid polypeptide formulations | |
| JP7356525B2 (ja) | ヒト抗ｒａｎｋｌ抗体の製剤及びその使用方法 | |
| EP2182983B1 (en) | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies | |
| US8784810B2 (en) | Treatment of amyloidogenic diseases | |
| JP7263320B2 (ja) | 抗ベータアミロイド抗体を含有する医薬組成物 | |
| CA2885862A1 (en) | Stable, low viscosity antibody formulation | |
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| HK1163504A (en) | Anti a beta antibody formulation | |
| HK1108132B (en) | Anti a beta antibody formulation | |
| HK1118723B (en) | Anti a beta antibody formulation | |
| WO2025199516A1 (en) | Compositions and methods for preserving or increasing lean muscle mass | |
| HK1196570B (en) | Anti a beta antibody formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |